184 related articles for article (PubMed ID: 17623986)
1. ESA therapy for anemia management: a call for civil discourse.
McAllister CJ
Nephrol News Issues; 2007 Jun; 21(7):49-50. PubMed ID: 17623986
[No Abstract] [Full Text] [Related]
2. We are overreacting to our hemoglobin fear.
Sadler JH
Nephrol News Issues; 2007 Jun; 21(7):48. PubMed ID: 17623985
[No Abstract] [Full Text] [Related]
3. The EPO/iron marriage: counseling needed.
Bralow S
Nephrol News Issues; 2007 Jun; 21(7):53, 55. PubMed ID: 17623987
[No Abstract] [Full Text] [Related]
4. Managing anemia. What do we do now? Views from Canada.
Mendelssohn DC; Muirhead N; Manns BJ
Nephrol News Issues; 2007 Jun; 21(7):55-7. PubMed ID: 17623988
[No Abstract] [Full Text] [Related]
5. [Anemia in chronic renal failure and erythropoietin].
Rosenlöf K
Duodecim; 1995; 111(15):1489-95. PubMed ID: 9244705
[No Abstract] [Full Text] [Related]
6. Continuous quality improvement (CQI) in rhu-Epo management: the outcome.
Descamps C; Van Waeleghem JP; Ysebaert D
EDTNA ERCA J; 1996; 22(3):22-6. PubMed ID: 10723328
[TBL] [Abstract][Full Text] [Related]
7. Target hemoglobin level for EPO therapy in CKD.
Parfrey PS
Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
[No Abstract] [Full Text] [Related]
8. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
9. [Anemia in the dialyzed patient].
Deray G
Soins; 2003 Oct; (679 Suppl):17. PubMed ID: 14621469
[No Abstract] [Full Text] [Related]
10. [Therapeutic guidelines for renal anemia in Japan].
Naito M; Akiba T
Nihon Rinsho; 2004 Jun; 62 Suppl 6():562-5. PubMed ID: 15250369
[No Abstract] [Full Text] [Related]
11. [How to optimize the concept of the variability of haemoglobin in dialysis patients].
Kessler M
Nephrol Ther; 2008 Dec; 4(7):547-8. PubMed ID: 18809370
[No Abstract] [Full Text] [Related]
12. Erythropoietin-resistant refractory renal anemia: effects of oral L-carnitine supplementation.
Kawabata M; Kasuga S; Hara H; Suyama S; Moriyama K; Takabatake T
Clin Nephrol; 2001 Mar; 55(3):265-6. PubMed ID: 11316253
[No Abstract] [Full Text] [Related]
13. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
14. Do hemodialysis patients need higher doses of erythropoietin if given intravenously rather than subcutaneously?
McMahon LP
Nat Clin Pract Nephrol; 2006 May; 2(5):246-7. PubMed ID: 16932434
[No Abstract] [Full Text] [Related]
15. Introduction to "A road map for intravenous iron and anemia management: preparing for the future".
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S1-4. PubMed ID: 19010256
[No Abstract] [Full Text] [Related]
16. European best practice guidelines 14-16: inadequate response to epoetin.
Hörl WH; Jacobs C; Macdougall IC; Valderrábano F; Parrondo I; Thompson K; Carveth BG
Nephrol Dial Transplant; 2000; 15 Suppl 4():43-50. PubMed ID: 11052148
[No Abstract] [Full Text] [Related]
17. Iron supplementation in renal anemia.
Fishbane S
Semin Nephrol; 2006 Jul; 26(4):319-24. PubMed ID: 16949471
[TBL] [Abstract][Full Text] [Related]
18. To treat or not to treat renal anemia of chronic kidney disease patients?
Tsubakihara Y
Ther Apher Dial; 2010 Jun; 14(3):235-9. PubMed ID: 20609177
[No Abstract] [Full Text] [Related]
19. Erythropoietin resistance in the treatment of the anemia of chronic renal failure.
Priyadarshi A; Shapiro JI
Semin Dial; 2006; 19(4):273-8. PubMed ID: 16893403
[TBL] [Abstract][Full Text] [Related]
20. Hemoglobin levels, quality of life, and survival.
Sadler JH; Meyer KB
Nephrol News Issues; 2007 Aug; 21(9):42-3. PubMed ID: 17722853
[No Abstract] [Full Text] [Related]
[Next] [New Search]
